Related Experiment Video
Updated: Jun 19, 2026
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Taxifolin-Functionalized Rivastigmine Liposomal Nanoformulation: A Synergistic Approach for Alzheimer's Disease
Manoyogambiga M1, Rajaganapathy Kaliyaperumal1
1Faculty of Pharmacy, Bharath Institute of Higher Education and Research, Selaiyur, Chennai-600073, Tamil Nadu, India.
Pharmaceutical Nanotechnology
|June 18, 2026
Summary
This study developed a novel Taxifolin-decorated Rivastigmine liposomal nanocarrier (Tax-Riva-Lipo) for Alzheimer's disease (AD). The nanocarrier offers combined cholinesterase inhibition, antioxidant, and anti-amyloid effects for improved neuroprotection and cognitive function.
Area of Science:
- Nanomedicine
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease (AD) involves cognitive decline, oxidative stress, and amyloid plaques.
- Current AD therapies offer symptomatic relief with limited brain delivery.
- Multifunctional nanocarriers are needed for synergistic therapeutic effects in AD.
Purpose of the Study:
- To formulate and evaluate a Taxifolin-decorated Rivastigmine liposomal nanocarrier (Tax-Riva-Lipo).
- To achieve synergistic neuroprotection via combined cholinesterase inhibition, antioxidant defense, and anti-amyloid activity.
Main Methods:
- Taxifolin was conjugated to DSPE-PEG and incorporated into Rivastigmine liposomes.
- Formulation characterized by DLS, TEM, FTIR, DSC.
- In vitro assays (release, enzyme inhibition, antioxidant, cell protection) and in vivo studies in an AD rat model were performed.
Main Results:
- Optimized Tax-Riva-Lipo showed uniform nanosize (~145 nm), high encapsulation (≈85%), and sustained release (48h).
- Demonstrated enhanced cholinesterase inhibition (AChE, BuChE), potent antioxidant activity, and significant neuroprotection (92% SH-SY5Y cell viability).
- In vivo studies revealed improved cognition, restored antioxidant enzymes, reduced inflammation, and preserved brain structure without toxicity.
Conclusions:
- Taxifolin functionalization provides synergistic antioxidant and anti-amyloid effects alongside sustained cholinesterase inhibition.
- Tax-Riva-Lipo is a promising nanotherapeutic platform for enhanced Alzheimer's disease management.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...